Reviewed by Emily Henderson, B.Sc.Dec 12 2022 Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab-;a novel, patient-tailored monoclonal antibody therapy-;showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped, Mount Sinai researchers reported in The Lancet. The researchers said the results indicate...
Tag: <span>monoclonal antibody therapy</span>
Post
Monoclonal antibody therapy and COVID-19
by Samantha Bochenek, University of Kentucky Credit: Pixabay/CC0 Public Domain Monoclonal antibody therapy is an infusion treatment that can reduce the severity of COVID-19. Here are some of the commonly asked questions about the treatment. Q: What are monoclonal antibodies and how do they work? A: Monoclonal antibodies are proteins created in a lab. The proteins mimic your...
Post
A novel monoclonal antibody therapy cuts LDL cholesterol by half in a high-risk patient population
by The Mount Sinai Hospital The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol—the so-called “bad” cholesterol—by 50 percent in patients with severe hypercholesterolemia whose condition is resistant to standard treatments, a phase 2 study from the Icahn School of Medicine of Mount Sinai and other global academic sites has found. Results from the study sponsored...